- Last Friday, Rep. Anna G. Eshoo (D-CA) announced that she and Rep. Joe Barton (R-TX) introduced H.R. 5629, the "Pathway for Biosimilars Act" (click here for summary; click here for text of bill). BIO immediately applauded the bill, while GPhA immediately denounced it. For more, visit FDA Law Blog; Pharmalot; or the WSJ Health Blog.
- Barr Labs and Teva are two of the world's largest, and most litigious, generic drug companies. Their CEO's gave extensive interviews to separate newspapers last week: Barr's CEO Bruce Downey to Investor's Business Daily and Teva's CEO Shlomo Yanai to Globes.
- We reported in January that Teva filed a citizen petition asking FDA to relist J&J's patent on Risperdal and to grant it 180-day exclusivity on the generic. Recently, FDA law blog and Patent Baristas reported that FDA denied Teva's petition on February 26, and Teva responded by filing suit against FDA on March 4. Also see: Reuters and Teva press release.
- The Wall St. Journal reported last week that Thailand is poised to disregard patents on several cancer drugs. The WSJ Health Blog has a summary of the article.
- Teva announced last month that it received approval for the first biosimilar G-CSF in Europe.
OBB RSS Feed
Disclaimer
- Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended for other attorneys. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-2017
« District Court Upholds Validity of P&G's Actonel Patent, Rejecting Teva's Obviousness Arguments | Main | Federal Circuit Addresses Effect of 271(e)(1) "Safe Harbor" in ITC Actions »
March 16, 2008
The comments to this entry are closed.
Search
Categories
- 180-Day Exclusivity
- 271(e)(1) Safe Harbor
- 271(e)(2) Jurisdiction
- 30-Month Stay
- Antitrust
- Authorized Generics
- Biosimilars
- Citizen Petitions
- Conferences
- Declaratory Judgment Jurisdiction
- FDA Announcements
- FDA Litigation
- Inequitable Conduct
- Infringement--271(g)
- Infringement--Direct
- Infringement--Indirect
- Inter Partes Review
- Orange Book Issues
- Paragraph IV Cases
- Patent Eligibility
- Patent Term Extension
- Pediatric Exclusivity
- Pharma Business News
- Preliminary Injunction
- Prosecution
- Section viii Statements
- Validity--Novelty
- Validity--Obviousness
- Validity--Section 101
- Validity--Section 112
Comments